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Abstract 
 Aim: To figure out the association of insulin resistance, serum 
resistin, insulin, SHBG, and free estradiol with the etiology, diagnosis, and 
the prognosis of postmenopausal breast cancer. Subjects and Methods: 
Serum levels of resistin, insulin, SHBG, free E2, glucose, and albumin were 
assayed in a case-control study of 40 obese postmenopausal breast cancer 
females and 40 apparently healthy obese postmenopausal controls. Results:  
Serum levels of resistin, insulin, and free E2 were significantly elevated in 
breast cancer patients (9.89±0.49, 23.68±2.95 and 9.34±3.02, respectively) 
compared with controls (8.24±0.63, 13.55±1.31 and 1.01±0.23, 
respectively). Insulin resistance (IR) was significantly greater in breast 
cancer patients (7.33±0.95) than controls (3.46±0.37). However, serum 
SHBG levels were significantly declined in breast cancer patients (42.93± 
2.52) compared with controls (64.2±4.89). Serum free E2 had the greatest 
significant area under the ROC curve, followed by insulin resistance, insulin, 
SHBG, and resistin. The odds ratio of serum resistin was 4.33 (95% CI=1.69 
– 11.06, P=0.002), insulin was 3.66 (95% CI=1.41 – 9.46, P=0.006), insulin 
resistance was 3.56 (95% CI=1.39 – 9.08, P=0.007), SHBG was 0.25 (95% 
CI=0.092-0.67, P=0.005), and free E2 was 5.21(95% CI=1.86 –14.52, 
P=0.002) in breast cancer patients. CONCLUSIONS: From this study, it 
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could be concluded that although insulin resistance, serum resistin, insulin, 
SHBG, and free E2 may have a role in the incidence and diagnosis of obese 
postmenopausal breast cancer females, these biochemical parameters cannot 
be used for the prognosis of these patients. Serum free E2 was the most 
superior diagnostic marker followed by insulin resistance, insulin, SHBG, 
and resistin. 
 
Keywords: Breast cancer, resistin, insulin, insulin resistance, SHBG, free 
estradiol, incidence, diagnosis, prognosis 
 
Introduction  
             Breast cancer is the most frequently diagnosed cancer and the 
leading cause of cancer death among females worldwide. [1] In Alexandria 
(Egypt) 2010, it accounted for about 47 % of all malignancies in females. 
Obesity is a worldwide epidemical that continues to grow at an alarming 
rate. [2] Moreover, obesity has been associated with the development of 
several malignancies, particularly hormone-dependent cancers such as 
ovarian, endometrial, and breast cancer. [3] 
            In addition, Adipose tissue has been recognized as an endocrine 
organ that plays a pivotal role in insulin resistance and glucose homeostasis 
by secreting signaling molecules known as adipocytokines such as resistin. 
The exact role of adipocytokines in glucose metabolism and their 
physiological functions in humans remains under investigation. However, 
adipocytokines which is directly synthesized in adipose tissue may influence 
mammary tumorigenesis by impacting both circulating and locally produced 
levels of the estrogen. [4] Resistin gained interest in correlation with cancer, 
and was strongly associated with tumors of gastrointestinal system and 
hematological system. [5] 
             Although insulin is involved primarily in the regulation of 
carbohydrates, lipids, and proteins metabolism, it also has a significant role 
as a growth factor. Thus, it stimulates cell mitosis and migration, and also 
inhibits apoptosis. These effects may actually be increased under conditions 
of insulin resistance and consequent impairment of insulin-regulated 
metabolic pathways. [6] Some studies have also demonstrated that elevated 
insulin levels and hyperinsulinemia are associated with poor prognosis in 
patients with breast cancer. Consequently, insulin resistance and alterations 
in levels of adipocytokines are associated with an increased risk of 
developing pre and postmenopausal breast cancer.  [7] 
               SHBG has been found to function as an active regulator of the 
steroid-signaling system in target tissues. In breast cancer cells, SHBG 
through its specific membrane receptor (SHBG-R) and second messenger 
system (cyclic AMP and protein kinase A), has not only effectively inhibits 
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estradiol induced cell proliferation, but also controls progesterone receptor 
expression at both the mRNA and protein levels. In addition, it has 
influences its function. [8]  
          Estradiol has been tied to the development and progression of breast 
cancer, ovarian cancer, and endometrial cancer. Estradiol affects target 
tissues by interacting with two nuclear hormone receptors called estrogen 
receptor α (ERα) and estrogen receptor β (ERβ). One of the functions of 
these estrogen receptors is gene expression. Once the hormone binds to the 
estrogen receptors, the hormone-receptor complexes then binds to 
specific DNA sequences causing an increase in cell division and DNA 
replication. [9] However, this study was carried out to investigate the role of 
serum resistin, insulin, insulin resistance, SHBG, and free estradiol in the 
incidence, diagnosis, and prognosis of breast cancer in postmenopausal 
females. 
 
Subjects and Methods 
Subjects 
             Eighty postmenopausal obese females were enrolled in this case-control 
study. Females were divided into two groups: Group I (Obese control group) 
included 40 apparently healthy obese women clinically free from any disease. 
Thus, their mean age and BMI were 58.43±1.13 years and 35±1.2 kg/m2, 
respectively. They were chosen from the staff members of the Medical Research 
Institute of Alexandria University (Egypt) and their relatives. Group II (Obese 
patient group) included 40 obese females having breast carcinoma of clinical 
stage II or III (10]. However, their mean age and BMI were 56.13±1.26 years and 
36±1.5 kg/m2, respectively.    
 This study was approved by the Ethical committee of the Medical 
Research Institute, Alexandria University, Egypt. Thus, informed consent was 
signed by each subject.  All subjects were recruited from the Experimental and 
Clinical Surgery, and the Cancer Management and Research Departments, 
Medical Research Institute, University of Alexandria within the period from June 
2011 to October 2011. Consequently, all patients had primary invasive breast 
carcinoma, with no clinical manifestation of infection, not receiving 
immunomodulating agent or blood transfusion for 3 weeks recently. Also, all 
patients and controls with diabetes, hypertension, hormone replacement therapy, 
and hypo or hyper-thyrodism were excluded from this study.   
 
Methods 
 To all patients, the following investigations were done:  full history 
recording, thorough clinical examination, routine laboratory investigations 
including complete blood count, bleeding and coagulation times, 
mammography of breast and ultrasonography of abdomen, radiological 
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investigations including x-ray chest, CT scan and bone scan when needed, 
and preoperative fine needle-aspiration cytology (FNAC) of the breast mass 
to establish the pathological diagnosis. 
 All patients had undergone modified radical mastectomy [11]. The 
clinicopathological data of tumor size, pathological grade, estrogen receptor 
(ER) status, progesterone receptor (PR) status, Her-2 expression, axillary 
lymph node involvement, and vascular invasion were collected from patients’ 
data sheets.  Each patient’s clinical stage was determined by the oncologist 
according to the TNM staging system [12] [table I].  
 After modified radical mastectomy, all breast cancer patients received 
adjuvant combination chemotherapy (5-fluorouracil, adriamycin and 
cyclophosphamide [FAC]) [13] for six cycles. The patients were evaluated 
clinically in the laboratory, and radiologically after three and six cycles of 
chemotherapy to estimate the clinical response. They were followed up for 45 
months of assessment of disease-free survival based on observation metastasis 
or local recurrence.  
Table (I). The clinicopathological data of breast cancer patients. 
Clinicopathological data Number 
(n) 
Percent 
(%) 
Tumor Size (cm) ≤5 
>5 
30 
10 
75% 
25% 
Patient's clinical Stage II 
III 
22 
18 
55% 
45% 
Tumor pathological grade II 
III 
27 
13 
67.5% 
32.5% 
Estrogen receptor status (ER) -ve 
+ve 
3 
37 
7.5% 
92.5% 
Progesterone receptor status 
(PR) 
-ve 
+ve 
10 
30 
25% 
75% 
Her-2 expression -ve 
+ve 
40 
0 
100% 
0% 
Axillary lymph node 
involvement 
-ve 
+ve 
4 
36 
10% 
90% 
Vascular invasion -ve 
+ve 
7 
33 
17.5% 
82.5% 
n: number of cases 
 
Laboratory Assays 
             In the morning, 5 ml fasting venous blood samples were withdrawn from 
each subject participating in this study. Blood samples were allowed to clot for 30 
minutes, and was centrifuged at 3000 rpm for 10 minutes to isolate serum. 10µl of 
serum were immediately used for assaying fasting glucose levels. The remaining 
serum was divided into aliquots and stored at -80oC until it was used for 
measuring the levels of resistin, insulin, SHBG, albumin, and total E2. Therefore, 
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all of these laboratory investigations were carried out at the radiation sciences 
department, Medical Research Institute, Alexandria University, Egypt. 
 
Determination of Serum Resistin Levels   
 Levels of resistin were determined using a ready-for-use enzyme-
linked immunosorbent assay (ELISA) kit according to the manufacturer's 
protocol (BioVender, USA). Briefly, standards, quality controls, and samples 
were incubated in microplate wells pre-coated with polyclonal anti-human 
resistin antibody. After 60 minutes incubation and washing, biotin-labelled 
second polyclonal anti-human resistin antibody was added. After 60 minutes 
incubation and washing, streptavidin-HRP conjugate was added. Also, after 
60 minutes incubation and washing, the substrate solution (TMB) was added. 
The reaction was stopped by the addition of acidic solution, and the 
absorbance of the resulting yellow product was measured at 450 nm. Serum 
resistin concentrations (ng/ml) were determined by referring to a standard 
curve. 
 
Determination of Serum Fasting Glucose Levels  
 Levels of serum glucose (mg/dl) were determined using a ready-for-
use colorimetric kit according to the manufacturer's protocol (Spinreact, 
Spain). Briefly, glucose is oxidized in the presence of glucose oxidase. The 
hydrogen peroxide formed reacts under catalysis of peroxidase with phenol 
and 4 – amino phenazone giving a red-violet quinoneimine dye. The 
intensity of the color is directly proportional to the glucose concentration in 
the samples. The absorbance of the sample and the standard were measured 
against the blank at 546 nm. 
 
Determination of Serum Fasting Insulin Levels  
 Serum insulin levels were determined using a ready-for-use 
immunoradiometric assay (IRMA) kit according to the manufacturer's 
protocol (Izotop, Hangerian). Briefly, the 125I-labeled signal-antibody binds 
to an epitope of the insulin molecule spatially different from that recognized 
by the biotin capture-antibody. The two antibodies react simultaneously with 
the antigen present in standards or samples, leading to the formation of a 
capture antibody-antigen-signal antibody complex, also referred to as 
“sandwich”. During a 2-hour incubation period, immuno-complex is 
immobilized to the reactive surface of streptavidin-coated test tubes. 
Reaction mixture is then discarded, test tubes washed, and radioactivity is 
measured for 1 minute in a gamma counter (perkin Elmer, Finland). Thus, 
the concentration of antigen is directly proportional to the radioactivity 
measured in test tubes. By constructing a calibration curve, the unknown 
serum concentrations of insulin (μIU/ml) were determined. 
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Evaluation of Insulin Resistance Status   
 Serum fasting insulin levels together with serum fasting glucose 
levels were grouped into the homeostatic model assessment (HOMA) index 
to estimate insulin resistance status as follows:                 
            HOMA-IR = [Fasting insulin (μIU/ml) x fasting glucose (mg/dl)] / 
405 [14]  
 
Determination of Serum SHBG Levels  
 Serum SHBG levels were determined using a ready-for-use IRMA kit 
according to the manufacturer's protocol (Izotop, Hangerian). The principle 
of the method was identical to that of insulin. By constructing a calibration 
curve, the unknown serum concentrations of SHBG (nmol/L) were 
determined.  
 
Determination of Serum Albumin Levels 
 Serum albumin levels (g/dl) were determined using a ready-for-use 
colorimetric kit according to the manufacturer's protocol (Diamond, Egypt). 
Briefly, albumin, in the presence of bromeresol green at a slightly acidic pH, 
produces a color change from yellow-green to green. The intensity of the 
color formed is directly proportional to the albumin concentration in the 
samples. The absorbance of the sample was measured against reagent blank 
at 630 nm. 
 
Determination of Serum Total Estradiol Levels 
 The levels of serum total E2 were determined using a ready-for-use 
radioimmunoassay (RIA) kit according to the manufacturer's protocol 
(Siemens, Germany). Briefly, 125I-labeled estradiol competes with estradiol 
in the sample for antibody molecules coated on the tube wall. After 
incubation, separation of bound from free radioactivity was achieved by 
decantation. The tube was then counted for 1 minute in a gamma counter 
(perkin Elmer, Finland). In addition, the levels (pg/ml) of total estradiol in 
the samples were determined by interpretation from a calibration curve. 
 
Quantification of Serum Free Estradiol Levels  
 Serum free E2 levels were estimated using an equation based on the 
law of mass action. This is dependent on the total E2 concentration and the 
fraction of E2 bound to albumin and SHBG according to the following 
equation [15]:    
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 Where [E2] is total E2 concentration, [E2F] is free E2 concentration, 
[SH] is SHBG concentration, [A] is albumin concentration, and KE A and KE 
SH are association constants for the binding of E2 to albumin and SHBG, 
respectively. Furthermore, we assumed the following values for the 
association constants: KE A = 6 x104 and KESH = 0.68 x 109. Then, we 
substituted it into equation 1.1. Serum free E2 levels were found by 
substitution in equation 1.1.  
 
Statistical Analysis 
 Statistical analysis was performed using SPSS 11.5 software package. 
Quantitative data were represented as mean and standard error. The data 
were abnormally distributed. Thus, non-parametric tests were used. The non-
parametric Mann-Whitney U-test was used for studying differences between 
obese control group and obese breast cancer group regarding serum resistin, 
insulin, insulin resistance, SHBG, and free estradiol. The non-parametric 
Spearman's correlation test was used for correlating studied serum 
parameters concentrations with clinicopathological data. In addition, the 
odd’s ratio was used to determine whether the serum marker is risky or 
protective for breast cancer. The diagnostic value of serum resistin, insulin, 
insulin resistance, SHBG, and free estradiol were compared using the 
Receiver Operating Characteristic (ROC) curve analysis. The Kaplan-Meier 
disease-free survival curve was applied to study the role of each preoperative 
serum biomarker to predict the disease-free survival of breast cancer 
patients. Therefore, P-value < 0.05 was considered to be statistically 
significant. 
 
Results 
Anthropometric Measurements of Breast Cancer Patients and Controls 
 For the control group, the mean±SE age was 58.43±1.13 years, and 
the mean±SE BMI was 35±1.2 kg/m2. For the breast cancer group, the 
mean±SE age was 56.13±1.26 years, while the BMI was 36±1.5 kg/m2. 
Because the cases and controls were frequency matched for age and BMI, 
there was no significant difference in the distribution of age and BMI 
between cases and controls.  
 
Serum Levels of Assayed Biochemical Parameters in Breast Cancer 
Patients and Controls 
 As shown in table II, the serum levels of resistin, insulin, and free E2 
were significantly elevated in breast cancer patients (9.89±0.49, 23.68±2.95, 
9.34±3.02, respectively) compared with controls (8.24±0.63, 13.55±1.31, 
1.01±0.23, respectively). Insulin resistance (IR) was significantly greater in 
breast cancer patients (7.33±0.95) than in controls (3.46±0.37). However, 
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serum SHBG levels were significantly declined in breast cancer patients 
(42.93± 2.52) compared with controls (64.2±4.89). 
Table (II). Mean±SE levels of assayed serum biochemical parameters in cases and controls. 
 
Biochemical parameter 
control group 
(n=40) 
Breast cancer group 
(n=40) 
P-value 
Resistin (ng/ml) 8.24±0.63 9.89±0.49 0.02* 
Insulin (μIU/ml) 13.55±1.31 23.68±2.95 0.003* 
(HOMA-IR) 3.46±0.37 7.33±0.95 0.001* 
SHBG (nmol/L) 64.20±4.89 42.93±2.52 0.003* 
Free E2 (pg/ml) 1.01±0.23 9.34±3.02 0.001* 
SE: Standard Error                        n: Sample Size 
*: Significance was compared with control group 
Significance was considered at p-value <0.05 
 
The Receiver Operating Characteristic (ROC) Curve Analysis for 
comparing the Diagnostic Value of the Assayed Biochemical Parameters 
among Breast Cancer Patients 
        The ROC curve analysis was used in the present study to evaluate 
and compare the diagnostic value of insulin resistance, serum resistin, 
insulin, SHBG, and free E2 depending on the area under the ROC curve 
(AUC). Consequently, the higher AUC corresponds to a better diagnostic 
test. As shown in table III and figures (1-3), serum free E2 showed a 
significant AUC (71.3%) (p=0.001), with sensitivity (60%) and specificity 
(82%) at a cut-off value (1.07pg/ml). Insulin resistance showed a significant 
AUC (70.8%) (p=0.001), with sensitivity (55%) and specificity (80%) at a 
cut-off value (4.9). Serum insulin showed a significant AUC (69.5%) 
(p=0.003), with sensitivity (55%) and specificity (75%) at a cut-off value 
(16.5 μIU /ml).  Serum SHBG showed a significant AUC (69.2%) (p=0.003), 
with sensitivity (52.5%) and specificity (80%) at a cut-off value (56.55nmol 
/L). Serum resistin showed a significant AUC (65.1%) (p=0.02), with 
sensitivity (72.5%) and specificity (65%) at a cut-off value (8.35ng/ml).  
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Figure (1). Graphical representation for the 
ROC curves of serum resistin and free E2. 
 
Figure (2). Graphical representation for the 
ROC curves of serum insulin and insulin 
resistance. 
 
Figure (3). Graphical representation for the ROC curve of serum SHBG. 
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Table (III). The ROC curve-based characteristics for resistin, insulin, insulin resistance, 
SHBG, and free E2 in breast cancer group. 
AUC: Area under the ROC curve *: Significance was considered at p-value <0.05 
 
Correlation between the Studied Biochemical Parameters and 
Clinicopathological Data of Breast Cancer Patients before Surgery 
 None of the assayed biochemical parameters showed a significant 
correlation with any of the clinicopathological data of breast cancer patients 
(all P values >0.05).  
 
The Association of Insulin Resistance, Serum Resistin, Insulin, SHBG, 
and Free Estradiol with Risk of Breast Cancer Incidence 
According to table (IV), the odds ratio of serum resistin was 4.33 (95% 
CI=1.69 – 11.06, P=0.002), insulin was 3.66 (95% CI=1.41 – 9.46, P=0.006 
), insulin resistance was 3.56 (95% CI=1.39 – 9.08, P=0.007), SHBG was 
0.25 (95% CI=0.092-0.67, P=0.005 ), and  free E2 was 5.21(95% CI=1.86 –
14.52, P=0.002 ) in breast cancer patients. 
Table (IV). The association of insulin resistance, serum resistin, insulin, SHBG, and free 
estradiol with risk of breast cancer incidence. 
Biochemical parameter 
Breast 
cancer 
group 
(n=40) 
Control 
group 
(n=40) 
Odds 
ratio 
(OR) 
 
95% CI 
 
p-value 
Resistin 
(ng/ml) 
<      8.35 ® 12 26 4.33 1.69 – 11.06 P=0.002 * ≥      8.35 28 14 
Insulin 
(μIU/ml) 
<      16.5® 19 33 3.66 1.41 – 9.46 P= 0.006* ≥      16.5 21 7 
Insulin 
resistance 
<        4.9® 17 29 
3.56 1.39 – 9.08 P=0.007* 
≥        4.9 23 11 
SHBG 
(nmol/L) 
<    56.55 8 20 0.25 0.092 - 0.67 P=0.005* 
≥    56.55® 32 20 
Free E2 
(pg/ml) 
<      1.07 ® 19 33 5.21 1.86 – 14.52 P=0.002 * ≥      1.07 21 7 
n= Sample Size; ® reference group; CI: Confidence Interval; *: Significance was considered 
at p-value<0.05. 
Serum biochemical parameter AUC p-value Cut-off 
Value 
Sensitivity 
% 
Specificity 
% 
Free E2 
(pg/ml) 
71.3 0.001* 1.07 60 82 
Insulin resistance 70.8 0.001* 4.9 55 80 
Insulin 
(μIU/ml) 
69.5 0.003* 16.5 55 75 
SHBG 
(nmol/L) 
69.2 0.003* 56.55 52.5 80 
Resistin 
(ng/ml) 
65.1 0.02* 8.35 72.5 65 
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Correlation between the Studied Biochemical Parameters and Disease-
free Survival of Breast Cancer Patients before Surgery 
 In the present study, patients were followed up for 45 months after 
completing 6 cycles of chemotherapy to study the correlation of the assayed 
biochemical parameters and patients disease–free survival (DFS) based on 
observation of any metastasis or local recurrence. To study this correlation, 
the Kaplan-Meir disease-free survival (DFS) curves were constructed. As 
shown in Figures (4-8),  Kaplan-Meir survival curves for breast cancer 
patients before surgery, revealed that the DFS of patients with elevated 
insulin resistance, serum resistin, insulin, and free E2 were non-significantly 
different from those with low levels of these biomarkers (P= 0.118, 0.872, 
0.379 and 0.652, respectively). Also, the DFS of patients with low serum 
SHBG before surgery was non-significantly different from those with high 
levels of SHBG (P=0.389) (Table V).  
 
Figure (4). Kaplan- Meier DFS of 
breast cancer patients in relation to 
preoperative serum resistin levels. 
 
 
Figure (5). Kaplan- Meier DFS of breast 
cancer patients in relation to preoperative 
serum insulin levels. 
 
Figure (6). Kaplan- Meier DFS of 
breast cancer patients in relation to 
preoperative insulin resistance. 
 
Figure (7). Kaplan- Meier DFS of 
breast cancer patients in relation to 
preoperative serum SHBG levels. 
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Figure (8). Kaplan- Meier DFS of breast cancer group in relation to preoperative serum free 
E2 levels. 
 
Table (V). Correlation between preoperative insulin resistance, serum resistin, insulin, 
SHBG, and free E2 with DFS of breast cancer patients. 
Biochemical 
parameters 
Cut-off 
value n 
Metastasis Non-metastasis DFS 
(M± SE) P-value No. % No. % 
Resistin 
( ng/ml)) 
< 8.35 (-
ve) 12 1 8.3 11 91.7 40.9±1.04 0.872 
≥ 8.35 
(+ve) 28 2 7.1 26 92.9 41.24±0.66 
Insulin 
(μIU/ml) 
<16.5 (-ve) 18 2 11.1 16 88.9 40.2±1.2 
0.379 ≥16.5 
(+ve) 22 1 4.5 21 95.5 41.9±0.1 
Insulin 
resistance 
< 4.9 (-ve) 17 0 0 17 100 41.14±0.6 
0.118 
≥ 4.9 (+ve) 23 3 13 20 87 40.05±0.22 
SHBG 
(nmol/L) 
≥ 56.55 (-
ve) 32 3 9.4 29 90.6 41.137±0.556 0.389 < 56.55 
(+ve) 8 0 0 8 100 40.047±0.95 
Free E2 
(pg/ml) 
< 1.07 (-
ve) 19 1 5.3 18 94.7 41.05±0.9 0.652 
≥ 1.07 
(+ve) 21 2 9.5 19 90.5 42.23±0.63 
DFS=Disease-free survival 
n=Sample size 
Significance was considered at p-value <0.05 
M± SE: Mean± standard error 
 
Discussion 
 Since the relationship of obesity with several forms of cancer has 
been known for a long time, researchers were trying to discuss the possible 
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role of adipocytokines in the regulation of carcinogenesis as another link 
between obesity and cancer. Resistin, an adipocytokine, recently gained 
interest in correlation with cancer and was strongly associated with tumors of 
gastrointestinal system and hematological system [16].  
 In the present study, there was a significant elevation in resistin levels 
in breast cancer patients compared to apparently normal controls. Our results 
were in agreement with Dalamaga  et al [17] who found that 
hyperresistinemia is involved in the development of postmenopausal breast 
cancer. Also, it reflects changes during postmenopausal breast cancer 
progression and therefore could be used as a biomarker for 
postmenopausal breast cancer. 
 Consequently, resistin inhibition could be used as an effective 
therapeutic strategy in breast cancer. On the other hand, our results disagreed 
with Gaudet et al [18], who found non-significant difference between breast 
cancer patients and normal controls regarding serum resistin. 
 In the present study, serum resistin showed a significant odd's ratio of 
4.33 (95% CI=1.69 – 11.06) which indicated that postmenopausal breast 
cancer females with serum resistin ≥ 8.35 ng/ml have 4 fold increased risk of 
getting breast cancer compared with those who have serum resistin < 8.35 
ng/ml.  Our results were in agreement with Dalamaga  et al [17].  Di-Simone 
et al [19] found that resistin enhanced matrix metal-oproteinase 2 (MMP-2) 
mRNA expression and protein synthesis, significantly reduced TIMP-1 and 
TIMP-2 synthesis, and it increased trophoblast-like cell invasiveness. 
Additionally, resistin induced the production of vascular endothelium growth 
factor (VEGF), and stimulated the formation of endothelial cell tube in vitro.  
On the other hand, our results disagreed with that of Gaudet et al [18]. 
 Because a previous study revealed that resistin is expressed not only 
from adipose tissue but also from monocytes and macrophages, and is 
correlated with C-reactive protein, soluble TNF-α, and IL-6 directly, the role 
of resistin as a marker of inflammation has received growing interest [20]. 
Chronic inflammation is known to be one of the causes of cancer 
development. Thus, the correlation between plasma resistin levels and breast 
cancer risk might be partly explained by inflammation [21]. These findings 
may strengthen and explain the risky role of resistin in carcinogenesis and 
progression of breast cancer. In view of this study, we can speculate that 
decreasing serum resistin levels may represent a therapeutic option for the 
reduction of breast cancer risk. This can be done via obesity control, 
increasing physical activity, and pharmacological intervention.  
 High insulin levels were most common in overweight women. 
Hyperinsulinemia induces proliferative tissue abnormalities because of the 
strong anabolic effect of insulin, which stimulates DNA synthesis and cell 
proliferation [22]. In the present study, serum insulin levels were 
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significantly elevated in breast cancer patients compared with apparently 
normal controls. Therefore, at the same time, serum insulin showed a 
significant odd's ratio of 3.66 (95% CI=1.41 – 9.46), which indicated that 
postmenopausal breast cancer females with serum insulin levels ≥16.5 
µIU/ml have about 4 fold increased risk of having breast cancer compared 
with those who have serum insulin levels < 16.5 µIU/ml. Our results were in 
agreement with Chowdhury [23] who reported the involvement of high 
insulin levels in the promotional stage of breast tumorigenesis and 
progression to express the metastatic phenotype, rather than the initiation and 
neoplastic transformation of the breast epithelial cell. On the other hand, our 
results disagreed with Autier et al [24], who found non-significant difference 
between breast cancer patients and controls regarding serum insulin levels. 
 Insulin resistance is one of the most pronounced metabolic changes 
associated with obesity. Although insulin is most widely known for its 
metabolic effects, studies showing that insulin has mitogenic effects on both 
normal and malignant breast tissue provided the biologic basis for an 
association of hyperinsulinemia with breast cancer [7]. In the current study, 
we estimated insulin resistance status in both patients and controls using 
the homeostatic model assessment (HOMA) method [25]. The results 
showed that there was a significant increase in insulin resistance in breast 
cancer patients compared to apparently normal controls. Also, insulin 
resistance showed a significant odd's ratio of 3.56 (95% CI=1.39 – 9.08), 
which indicated that postmenopausal breast cancer females with insulin 
resistance ≥ 4.9 have about 4 fold increased risk of having breast cancer 
compared with those who have serum insulin resistance < 4.9. Our results 
confirmed the results of Al Awadhi et al [7] and Formica et al [26]. 
Therefore, they found that insulin resistance has causative and prognostic role 
in breast cancer development and progression in postmenopausal patients. 
 However, because obesity is often complicated with 
hyperinsulinemia and insulin could stimulate cellular mitosis, insulin 
resistance probably might be one of the mechanisms underlying the 
relationship between obesity and breast cancer risk. Various explanations 
have been proposed for the association of insulin and insulin resistance with 
breast cancer incidence in obese postmenopausal females as follows: (a) 
Chronic hyperinsulinemia in affected individuals may promote cancer as 
insulin can exert its oncogenic potential via abnormal stimulation of multiple 
cellular signaling cascades, enhancing growth factor-dependant cell 
proliferations, and /or by directly affecting cell metabolism. (b) Insulin 
increases bioactivity of IGF-1 by enhancing hepatic IGF-1 synthesis and by 
reducing hepatic protein production of the insulin–like growth factor binding 
protein-1(IGFB-P-1) and 2(IGFB-P-2) [27]. Therefore, although insulin can 
directly induce tumor growth, many of its mitogenic and antiapoptotic 
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effects are operating through the IGF-1 system as reported in individuals 
with high levels of circulating IGF-1, in which an increased risk of 
developing certain types of tumors, in particular breast cancer, has been 
documented [28]. (c) Insulin, by reducing SHBG levels, exerts a positive 
effect on estrogen bioavailability, therefore increasing the risk of breast 
cancer. (d) obesity, the most common cause of insulin resistance, is 
increasingly recognized as a low grade inflammatory state in which 
overproduction of certain molecules such as free fatty acids, IL6, 
adiponectin, TNF-α, plasminogen activator inhibitor-1, and monocyte 
chemoattractant protein (MCP-1) can play a role in malignant transformation 
and /or cancer progression. In this context, chronic hyperglycemia and 
increased oxidative stress may also contribute to increased cancer risk. 
However, these lines of evidence support the concept that a relationship 
exists between insulin resistance and cancer.      
 The sex hormone-binding globulin (SHBG) transports androgens 
and estradiol in blood and modulates their bioavailable fraction and access to 
target cells. Also, SHBG directly regulates the incidence of breast tissue 
[29]. In the current study, there was a significant decline in SHBG levels in 
breast cancer patients compared with apparently normal controls. Thus, 
serum SHBG showed a significant odd's ratio of 0.25 (95% CI=0.092- 0.67), 
which indicated that postmenopausal breast cancer females with serum 
SHBG levels < 56.55 nmol/ml have about 4 fold increased risk of having 
breast cancer compared with those who have serum SHBG levels ≥ 56.55 
nmol/ml. Our results were in agreement with that of Woolcott et al [30]. 
 The reduced levels of SHBG recorded in the current study is assumed 
to be due to higher circulating insulin concentration detected in obese breast 
cancer subjects, as basal secretion of SHBG by cultured human hepatoma cell 
line (HePG2) was greatly reduced by the physiological concentration of 
insulin [31]. Previous studies showed that in vivo diazoxide treatment, 
resulting in decreased insulin levels, produced a significant increase in SHBG 
[32]. Therefore, these intervention studies suggested that insulin negatively 
regulates hepatic production of SHBG.  
 Sex steroid hormones play a central role in the development of breast 
cancer. Collaborative analysis using individual data from prospective studies 
has demonstrated significant relationships between concentrations of 
endogenous sex hormones and breast cancer risk in postmenopausal women 
[33]. Sex hormones generally circulate bound to plasma proteins with only a 
very small fraction circulating unbound (between 1 and 5%). The majority of 
the protein binding to estradiol is provided by SHBG and albumin. Initially, 
it was hypothesized that it was only the free (unbound) fractions of sex 
hormones that were biologically active [15].  
European Scientific Journal October 2015 /SPECIAL/ edition Vol.2   ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
 
163 
 In the present study, there was a significant increase in the serum 
levels of free E2 in breast cancer patients compared with apparently normal 
controls. Serum free E2 showed a significant odd's ratio of 5.21(95% 
CI=1.86 – 14.52), which indicated that postmenopausal breast cancer 
females with serum free E2 levels ≥1.07 pg/ml have about 5 fold increased 
risk of having breast cancer compared with those who have serum free E2 
levels <1.07 pg/ml. Our results confirmed those of Fourkala et al [34] who 
reported that the risk for breast cancer increased significantly with increasing 
concentrations of all sex hormones examined: total estradiol, free estradiol, 
non-sex hormone-binding globulin (SHBG)-bound estradiol (which 
comprises of free and albumin-bound estradiol), estrone, estrone sulfate, 
androstenedione, dehydroepiandrosterone, dehydroepian-drosterone sulfate, 
and testosterone. On the other hand, our results disagreed with  Awio et al 
[35] who found non-significant difference between breast cancer and 
controls regarding serum free E2. 
 This estrogen excess is explained by over activity of aromatase 
cytochrome P450 enzyme which is expressed at high levels in white adipose 
tissue and is responsible for a key step in the biosynthesis of estrogen. 
Moreover, it is well known that SHBG through its specific membrane 
receptor (SHBG-R), cAMP and protein kinase A, inhibits the estradiol-
induced cell proliferation. Accordingly, the decreased levels of SHBG 
observed in this study may be another contributing factor causing elevated 
levels of free estradiol [36]. It was reported that the effect of estradiol on 
breast cancer risk would be observed most strongly for the fraction of 
estradiol that is not tightly bound by SHBG. This is because this fraction of 
estradiol (which comprises of free and albumin bound estradiol) is readily 
able to enter cells, whereas SHBG-bound estradiol does not [37]. Our results 
supported this hypothesis. 
 In the present study, the receiver operating characteristic (ROC) 
curve analysis was used to compare the diagnostic accuracy of each 
biomarker based on the area under the curve (AUC) for each parameter. A 
marker having a greater AUC is a superior diagnostic marker to another 
marker having a smaller AUC. From the results of the present study, serum 
free E2 was the most superior diagnostic marker followed by insulin 
resistance, insulin, SHBG, and resistin. In the current study, all the AUCs 
were greater than 62%. Therefore, this means that each assayed biochemical 
parameter can be used as a diagnostic marker with an acceptable 
performance. Up to the best of our knowledge, this is the first study which 
evaluates and compares the diagnostic and values of insulin resistance status, 
serum levels of resistin, insulin, SHBG, and free E2 using the ROC curve 
analysis.          
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 In the current study, insulin resistance status, serum levels of resistin, 
insulin, SHBG, and free E2 were non-significantly correlated with both 
clinicopathological features and disease-free survival of breast cancer 
patients. Therefore, this means that none of the assayed biochemical 
parameters can be used as a prognostic marker in obese postmenopausal 
breast cancer patients. Our result disagrees with the results of Gennari et al 
[38] and Assiri et al [39].  This contradiction between our results and 
previous ones may be due to the small sample size, short time follow up, and 
the conditions of the studies including the methodological differences. 
 
Conclusion 
 From the current study, it could be concluded that: (a) all of these 
biochemical parameters can have a role in the etiology of postmenopausal 
breast cancer; (b) all of these biochemical parameters can be used to 
diagnose postmenopausal breast cancer patients with free E2 as the most 
superior diagnostic marker followed by insulin resistance, insulin, SHBG, 
and resistin; and (c) none of these biochemical parameters has a respectable 
prognostic role in postmenopausal breast cancer patients. 
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